Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Marks remarkable acceleration in innovation using AI technology
Innovent will supply sintilimab for the collaborated clinical trial
NEIAFMR to be developed as the national hub for folk medicine
US FDA approval based on NEURO-TTRansform Phase III results
The plant is yet to start commercial operations
Subscribe To Our Newsletter & Stay Updated
